ABSTRACT
Idiopathic pulmonary fibrosis (PF) is a type of chronic lung disease. Here, we investigated the effect of induced pluripotent stem cell (iPSC)-derived exosomes (iPSC-exosomes) on M2-type macrophages which play a critical role in pulmonary fibrosis. Exosomes were purified from the conditioned medium of iPSCs. Mice models of pulmonary fibrosis were established by intratracheal instillation with 5 mg/kg bleomycin. Thereafter, the histopathological changes and collagen deposition were detected by HE and masson staining. Meanwhile the level of M2-type macrophages was elevated by immunofluorescence staining with F4/80 and Arg-1. Luciferase reporter assay was conducted to verify the binding of miR-302a-3p to ten-eleven translocation 1 (TET1). Our results showed that, after treatment with iPSC-exosomes, the pulmonary fibrosis induced by bleomycin was relieved, with less collagen deposition. In addition, the increased M2-type macrophages in PF mice were reduced upon treatment with iPSC-exosomes. Moreover, we found that the iPSC-exosomes showed higher level of miR-302a-3p. Interestingly, the level of miR-302a-3p in the lungs of PF mice was increased upon treatment with iPSC-exosomes. Furthermore, we verified that TET1 was a direct target of miR-302a-3p. Up-regulation of miR-302a-3p or TET1 silencing repressed M2-type macrophages. Down-regulation of miR-302a-3p abolished the beneficial effects of iPSC-exosomes on pulmonary fibrosis. Collectively, our study revealed that iPSC-exosomes delivered miR-302a-3p to suppress the M2-type macrophages via targeting TET1, thus mitigating pulmonary fibrosis. This study indicates that iPSC-exosomes may become a potential therapeutic agent for pulmonary fibrosis.
Subject(s)
DNA-Binding Proteins/metabolism , Exosomes/metabolism , Induced Pluripotent Stem Cells/chemistry , Macrophages/metabolism , MicroRNAs/metabolism , Proto-Oncogene Proteins/metabolism , Pulmonary Fibrosis/drug therapy , Pulmonary Fibrosis/genetics , Animals , Bleomycin/toxicity , Disease Models, Animal , Embryo, Mammalian/cytology , Exosomes/chemistry , Fibroblasts/chemistry , Fibroblasts/metabolism , Induced Pluripotent Stem Cells/metabolism , Male , Mice , Mice, Inbred C57BL , MicroRNAs/genetics , Pulmonary Fibrosis/chemically induced , Pulmonary Fibrosis/pathology , RAW 264.7 Cells , Signal TransductionABSTRACT
Goatpox, caused by goatpox virus (GTPV), is an acute feverish and contagious disease in goats often associated with high morbidity and high mortality. To resolve potential safety risks and vaccination side effects of existing live attenuated goatpox vaccine (AV41), two Semliki forest virus (SFV) replicon-based bicistronic expression DNA vaccines (pCSm-AAL and pCSm-BAA) which encode GTPV structural proteins corresponding to the Vaccinia virus proteins A27, L1, A33, and B5, respectively, were constructed. Then, theirs ability to induce humoral and cellular response in mice and goats, and protect goats against virulent virus challenge were evaluated. The results showed that, vaccination with pCSm-AAL and pCSm-BAA in combination could elicit strong humoral and cellular responses in mice and goats, provide partial protection against viral challenge in goats, and reduce disease symptoms. Additionally, priming vaccination with the above-mentioned DNA vaccines could significantly reduce the goats' side reactions from boosting vaccinations with current live vaccine (AV41), which include skin lesions at the inoculation site and fevers. Data obtained in this study could not only facilitate improvement of the current goatpox vaccination strategy, but also provide valuable guidance to suitable candidates for evaluation and development of orthopoxvirus vaccines.
Subject(s)
Capripoxvirus/immunology , Goats/immunology , Semliki forest virus/immunology , Vaccines, DNA/immunology , Viral Structural Proteins/immunology , Viral Vaccines/immunology , Animals , Antibodies, Viral/blood , Antibodies, Viral/immunology , Antibody Formation , Capripoxvirus/genetics , Cell Proliferation , Goats/virology , Immunity, Cellular , Mice , Mice, Inbred BALB C , Neutralization Tests , Poxviridae Infections/immunology , Semliki forest virus/genetics , T-Lymphocytes/immunology , Vaccination , Viral Structural Proteins/geneticsABSTRACT
DNA-based vaccination is an attractive alternative for overcoming the disadvantages of inactivated virus vaccines; however, DNA vaccines alone often generate only weak immune responses. In this study, the efficacy of LMS as a chemical adjuvant on a DNA vaccine (pVIR-P12A-IL18-3C) encoding the P1-2A and 3C genes of the FMDV and swine IL-18, which provides protection against FMDV challenge, was tested. All test pigs were administered booster vaccinations 28 days after the initial inoculation, and were challenged with 1000 ID50 FMDV O/NY00 20 days after the booster vaccination. Positive and negative control groups were inoculated with inactivated virus vaccine and PBS respectively. The DNA vaccine plus LMS induced greater humoral and cell-mediated responses than the DNA vaccine alone, as evidenced by higher concentrations of neutralizing and specific anti-FMDV antibodies, and by higher concentrations of T-lymphocyte proliferation and IFN-y production, respectively. FMDV challenge revealed that the DNA vaccine plus LMS provided higher protection than the DNA vaccine alone. This study demonstrates that LMS may be useful as an adjuvant for improving the protective efficiency of DNA vaccination against FMDV in pigs.
Subject(s)
Adjuvants, Pharmaceutic/administration & dosage , Levamisole , Vaccines, DNA , Viral Vaccines , Animals , Antibodies, Viral/blood , Foot-and-Mouth Disease/immunology , Foot-and-Mouth Disease/prevention & control , Foot-and-Mouth Disease/virology , Foot-and-Mouth Disease Virus/immunology , Foot-and-Mouth Disease Virus/pathogenicity , Interferon-gamma/metabolism , Interleukin-18/administration & dosage , Interleukin-18/immunology , Levamisole/administration & dosage , Levamisole/immunology , Lymphocyte Activation/immunology , Neutralization Tests , Swine , Swine Diseases/immunology , Swine Diseases/prevention & control , Swine Diseases/virology , T-Lymphocytes/immunology , Treatment Outcome , Vaccines, DNA/administration & dosage , Vaccines, DNA/immunology , Viral Vaccines/administration & dosage , Viral Vaccines/genetics , Viral Vaccines/immunologyABSTRACT
Two recombinant fowlpox viruses (rFPV-P1 and rFPV-IL18-2AP12A) containing foot-and-mouth disease virus (FMDV) capsid polypeptide, 3C coding regions of O/NY00 were evaluated to determine their abilities to induce humoral and cellular responses in the presence or absence of swine IL-18 as genetic adjuvant. The ability to protect swine against homologous virus challenge was examined. All swine were given booster vaccinations at 21 days after the initial inoculation and were challenged 10 days after the booster vaccination. Control groups were inoculated with wild-type fowlpox virus (wtFPV). All animals vaccinated with rFPV-P12A and rFPV-IL18-P12A developed specific anti-FMDV ELISA antibody and neutralizing antibody and T-lymphocyte proliferation was observed. Cellular immune function was evaluated via examination of IFN-gamma production in swine peripheral blood serum. The results demonstrate the potential viability of a fowlpox virus-based recombinant vaccine in the control and prevention of FMDV infections.
Subject(s)
Cysteine Endopeptidases/immunology , Foot-and-Mouth Disease Virus/immunology , Foot-and-Mouth Disease/prevention & control , Interleukin-18/immunology , Swine Diseases/prevention & control , Swine/immunology , Viral Proteins/immunology , Viral Vaccines/immunology , 3C Viral Proteases , Adjuvants, Immunologic/genetics , Adjuvants, Immunologic/pharmacology , Animals , Antibodies, Viral/blood , Capsid Proteins/genetics , Capsid Proteins/immunology , Cysteine Endopeptidases/genetics , Enzyme-Linked Immunosorbent Assay/veterinary , Foot-and-Mouth Disease/immunology , Foot-and-Mouth Disease Virus/genetics , Fowlpox virus/genetics , Fowlpox virus/immunology , Interferon-gamma/blood , Interleukin-18/genetics , Neutralization Tests/veterinary , Plasmids/genetics , Plasmids/immunology , Random Allocation , Swine Diseases/immunology , Swine Diseases/virology , Vaccination/methods , Vaccination/veterinary , Vaccines, Synthetic/immunology , Vaccines, Synthetic/pharmacology , Viral Proteins/genetics , Viral Vaccines/pharmacologyABSTRACT
Two recombinant fowlpox viruses (rFPV-ORF5-ORF3 and rFPV-IL-18-ORF5-ORF3) containing the ORF5/ORF3 cDNAs of PRRSV (strain Chang Chun) and IL-18 of swine were constructed and evaluated for theirs abilities to induce humoral and cellular responses in piglets. In addition, their abilities to protect piglets against homologous virus challenge were examined. All piglets were given booster vaccinations at 21 days after the initial inoculation, and all piglets were challenged at 60 after the initial inoculation. Control groups were inoculated with wild-type fowlpox virus (wtFPV). All animals vaccinated with rFPV-ORF5-ORF3 and rFPV-IL-18-ORF5-ORF3 developed specific anti-PRRSV ELISA antibody and neutralizing antibody, as well as T-lymphocyte proliferation response. To evaluate the cellular immune function, IFN-gamma production in pigs serum and T-lymphocytes (CD4 and CD8 T cells) in peripheral blood were examined. Following challenge with a pathogenic strain of PRRSV (strain Chang Chun), piglets inoculated with recombinant fowlpox virus (rFPV) showed lower (P<0.05) temperature, viremia and virus load in bronchial lymph nodes than control animals, suggesting the establishment of partial protection against PRRSV infection. The results demonstrated the potential use of a fowlpox virus-based recombinant vaccine in the control and prevention of PRRSV infections.
Subject(s)
Fowlpox virus/immunology , Interleukin-18/immunology , Porcine Reproductive and Respiratory Syndrome/immunology , Porcine Reproductive and Respiratory Syndrome/prevention & control , Porcine respiratory and reproductive syndrome virus/immunology , Vaccines, Synthetic/immunology , Viral Envelope Proteins/immunology , Viral Vaccines/immunology , Adjuvants, Immunologic/genetics , Animals , Antibodies, Viral/blood , Body Temperature , Cell Proliferation , Cells, Cultured , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Fowlpox virus/genetics , Immunization, Secondary , Interferon-gamma/biosynthesis , Interferon-gamma/blood , Interleukin-18/genetics , Lymph Nodes/virology , Neutralization Tests , Porcine respiratory and reproductive syndrome virus/genetics , Swine , T-Lymphocytes/immunology , Vaccines, Synthetic/genetics , Viral Envelope Proteins/genetics , Viral Vaccines/genetics , ViremiaABSTRACT
Foot-and-mouth disease virus (FMDV) is an important pathogen with worldwide economic consequences. Consequently, an important goal is the development of a vaccine that can provide rapid protection while overcoming the potential risk associated with the production of conventional inactivated vaccines. An important secondary feature of the vaccine would be the ability to distinguish vaccinated from infected animals. A recombinant fowlpox virus (vUTAL3CP1) containing FMDV capsid polypeptide and 3C coding regions of O/NY00 was constructed and evaluated for its ability to induce humoral and cellular responses in mice and guinea pigs. In addition, the ability to protect guinea pigs against homologous virus challenge was examined. Mice and guinea pigs were given booster vaccinations twice and once, respectively, and guinea pigs were challenged 20 days after the booster vaccination. Control groups included animals inoculated with commercial vaccine, fowlpox virus or phosphate-buffered saline (PBS). All animals vaccinated with vUTAL3CP1 developed specific anti-FMDV antibody and neutralizing antibody, as well as T lymphocyte proliferation response and CTL cytotoxic activity. Three of four guinea pigs vaccinated with vUTAL3CP1 were completely protected from viral challenge. The results demonstrated the potential of a fowlpox virus-based recombinant FMD vaccine.